Psilocybin with psychological support for treatment-resistant depression: six-month follow-up. Carhart-Harris, R., L., Bolstridge, M., Day, C., M., Rucker, J., J., Watts, R., Erritzoe, D., Kaelen, M., Giribaldi, B., Bloomfield, M., Pilling, S., Rickard, J., A., Forbes, B., Feilding, A., Taylor, D., Curran, H., V., & Nutt, D., J. Psychopharmacology, 235(2):399-408, 2018. ![Psilocybin with psychological support for treatment-resistant depression: six-month follow-up. [link]](https://bibbase.org/img/filetypes/link.svg "link")
Website abstract bibtex RATIONALE Recent clinical trials are reporting marked improvements in mental health outcomes with psychedelic drug-assisted psychotherapy. OBJECTIVES Here, we report on safety and efficacy outcomes for up to 6 months in an open-label trial of psilocybin for treatment-resistant depression. METHODS Twenty patients (six females) with (mostly) severe, unipolar, treatment-resistant major depression received two oral doses of psilocybin (10 and 25 mg, 7 days apart) in a supportive setting. Depressive symptoms were assessed from 1 week to 6 months post-treatment, with the self-rated QIDS-SR16 as the primary outcome measure. RESULTS Treatment was generally well tolerated. Relative to baseline, marked reductions in depressive symptoms were observed for the first 5 weeks post-treatment (Cohen's d = 2.2 at week 1 and 2.3 at week 5, both p < 0.001); nine and four patients met the criteria for response and remission at week 5. Results remained positive at 3 and 6 months (Cohen's d = 1.5 and 1.4, respectively, both p < 0.001). No patients sought conventional antidepressant treatment within 5 weeks of psilocybin. Reductions in depressive symptoms at 5 weeks were predicted by the quality of the acute psychedelic experience. CONCLUSIONS Although limited conclusions can be drawn about treatment efficacy from open-label trials, tolerability was good, effect sizes large and symptom improvements appeared rapidly after just two psilocybin treatment sessions and remained significant 6 months post-treatment in a treatment-resistant cohort. Psilocybin represents a promising paradigm for unresponsive depression that warrants further research in double-blind randomised control trials.
@article{
title = {Psilocybin with psychological support for treatment-resistant depression: six-month follow-up.},
type = {article},
year = {2018},
identifiers = {[object Object]},
keywords = {5-HT2AR,Depression,Hallucinogen,Mood,Psilocybin,Psychedelic,Psychotherapy,Serotonin,Treatment-resistant depression},
pages = {399-408},
volume = {235},
websites = {https://doi.org/10.1007/s00213-017-4771-x,http://www.ncbi.nlm.nih.gov/pubmed/29119217%0Ahttp://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC5813086},
id = {22417819-6026-3adb-a449-193438d32d12},
created = {2019-07-05T23:01:37.593Z},
accessed = {2019-07-06},
file_attached = {false},
profile_id = {38c6dbcb-2394-3f18-9217-58d777c08c69},
group_id = {d9389c6c-8ab5-3b8b-86ed-33db09ca0198},
last_modified = {2019-10-23T13:46:51.508Z},
tags = {Disc:Psychopharmacology,OA},
read = {false},
starred = {false},
authored = {false},
confirmed = {false},
hidden = {false},
private_publication = {false},
abstract = {RATIONALE Recent clinical trials are reporting marked improvements in mental health outcomes with psychedelic drug-assisted psychotherapy. OBJECTIVES Here, we report on safety and efficacy outcomes for up to 6 months in an open-label trial of psilocybin for treatment-resistant depression. METHODS Twenty patients (six females) with (mostly) severe, unipolar, treatment-resistant major depression received two oral doses of psilocybin (10 and 25 mg, 7 days apart) in a supportive setting. Depressive symptoms were assessed from 1 week to 6 months post-treatment, with the self-rated QIDS-SR16 as the primary outcome measure. RESULTS Treatment was generally well tolerated. Relative to baseline, marked reductions in depressive symptoms were observed for the first 5 weeks post-treatment (Cohen's d = 2.2 at week 1 and 2.3 at week 5, both p < 0.001); nine and four patients met the criteria for response and remission at week 5. Results remained positive at 3 and 6 months (Cohen's d = 1.5 and 1.4, respectively, both p < 0.001). No patients sought conventional antidepressant treatment within 5 weeks of psilocybin. Reductions in depressive symptoms at 5 weeks were predicted by the quality of the acute psychedelic experience. CONCLUSIONS Although limited conclusions can be drawn about treatment efficacy from open-label trials, tolerability was good, effect sizes large and symptom improvements appeared rapidly after just two psilocybin treatment sessions and remained significant 6 months post-treatment in a treatment-resistant cohort. Psilocybin represents a promising paradigm for unresponsive depression that warrants further research in double-blind randomised control trials.},
bibtype = {article},
author = {Carhart-Harris, Robin Lester and Bolstridge, Mark and Day, Camilla M.J. and Rucker, James J.H. and Watts, Rosalind and Erritzoe, David and Kaelen, Mendel and Giribaldi, B and Bloomfield, Michael and Pilling, Steve and Rickard, James A. and Forbes, Ben and Feilding, Amanda and Taylor, David and Curran, H. Valerie and Nutt, David J.},
journal = {Psychopharmacology},
number = {2}
}
Downloads: 0
{"_id":"R2D3vvH7LiESAqr9k","bibbaseid":"carhartharris-bolstridge-day-rucker-watts-erritzoe-kaelen-giribaldi-etal-psilocybinwithpsychologicalsupportfortreatmentresistantdepressionsixmonthfollowup-2018","authorIDs":[],"author_short":["Carhart-Harris, R., L.","Bolstridge, M.","Day, C., M.","Rucker, J., J.","Watts, R.","Erritzoe, D.","Kaelen, M.","Giribaldi, B.","Bloomfield, M.","Pilling, S.","Rickard, J., A.","Forbes, B.","Feilding, A.","Taylor, D.","Curran, H., V.","Nutt, D., J."],"bibdata":{"title":"Psilocybin with psychological support for treatment-resistant depression: six-month follow-up.","type":"article","year":"2018","identifiers":"[object Object]","keywords":"5-HT2AR,Depression,Hallucinogen,Mood,Psilocybin,Psychedelic,Psychotherapy,Serotonin,Treatment-resistant depression","pages":"399-408","volume":"235","websites":"https://doi.org/10.1007/s00213-017-4771-x,http://www.ncbi.nlm.nih.gov/pubmed/29119217%0Ahttp://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC5813086","id":"22417819-6026-3adb-a449-193438d32d12","created":"2019-07-05T23:01:37.593Z","accessed":"2019-07-06","file_attached":false,"profile_id":"38c6dbcb-2394-3f18-9217-58d777c08c69","group_id":"d9389c6c-8ab5-3b8b-86ed-33db09ca0198","last_modified":"2019-10-23T13:46:51.508Z","tags":"Disc:Psychopharmacology,OA","read":false,"starred":false,"authored":false,"confirmed":false,"hidden":false,"private_publication":false,"abstract":"RATIONALE Recent clinical trials are reporting marked improvements in mental health outcomes with psychedelic drug-assisted psychotherapy. OBJECTIVES Here, we report on safety and efficacy outcomes for up to 6 months in an open-label trial of psilocybin for treatment-resistant depression. METHODS Twenty patients (six females) with (mostly) severe, unipolar, treatment-resistant major depression received two oral doses of psilocybin (10 and 25 mg, 7 days apart) in a supportive setting. Depressive symptoms were assessed from 1 week to 6 months post-treatment, with the self-rated QIDS-SR16 as the primary outcome measure. RESULTS Treatment was generally well tolerated. Relative to baseline, marked reductions in depressive symptoms were observed for the first 5 weeks post-treatment (Cohen's d = 2.2 at week 1 and 2.3 at week 5, both p < 0.001); nine and four patients met the criteria for response and remission at week 5. Results remained positive at 3 and 6 months (Cohen's d = 1.5 and 1.4, respectively, both p < 0.001). No patients sought conventional antidepressant treatment within 5 weeks of psilocybin. Reductions in depressive symptoms at 5 weeks were predicted by the quality of the acute psychedelic experience. CONCLUSIONS Although limited conclusions can be drawn about treatment efficacy from open-label trials, tolerability was good, effect sizes large and symptom improvements appeared rapidly after just two psilocybin treatment sessions and remained significant 6 months post-treatment in a treatment-resistant cohort. Psilocybin represents a promising paradigm for unresponsive depression that warrants further research in double-blind randomised control trials.","bibtype":"article","author":"Carhart-Harris, Robin Lester and Bolstridge, Mark and Day, Camilla M.J. and Rucker, James J.H. and Watts, Rosalind and Erritzoe, David and Kaelen, Mendel and Giribaldi, B and Bloomfield, Michael and Pilling, Steve and Rickard, James A. and Forbes, Ben and Feilding, Amanda and Taylor, David and Curran, H. Valerie and Nutt, David J.","journal":"Psychopharmacology","number":"2","bibtex":"@article{\n title = {Psilocybin with psychological support for treatment-resistant depression: six-month follow-up.},\n type = {article},\n year = {2018},\n identifiers = {[object Object]},\n keywords = {5-HT2AR,Depression,Hallucinogen,Mood,Psilocybin,Psychedelic,Psychotherapy,Serotonin,Treatment-resistant depression},\n pages = {399-408},\n volume = {235},\n websites = {https://doi.org/10.1007/s00213-017-4771-x,http://www.ncbi.nlm.nih.gov/pubmed/29119217%0Ahttp://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC5813086},\n id = {22417819-6026-3adb-a449-193438d32d12},\n created = {2019-07-05T23:01:37.593Z},\n accessed = {2019-07-06},\n file_attached = {false},\n profile_id = {38c6dbcb-2394-3f18-9217-58d777c08c69},\n group_id = {d9389c6c-8ab5-3b8b-86ed-33db09ca0198},\n last_modified = {2019-10-23T13:46:51.508Z},\n tags = {Disc:Psychopharmacology,OA},\n read = {false},\n starred = {false},\n authored = {false},\n confirmed = {false},\n hidden = {false},\n private_publication = {false},\n abstract = {RATIONALE Recent clinical trials are reporting marked improvements in mental health outcomes with psychedelic drug-assisted psychotherapy. OBJECTIVES Here, we report on safety and efficacy outcomes for up to 6 months in an open-label trial of psilocybin for treatment-resistant depression. METHODS Twenty patients (six females) with (mostly) severe, unipolar, treatment-resistant major depression received two oral doses of psilocybin (10 and 25 mg, 7 days apart) in a supportive setting. Depressive symptoms were assessed from 1 week to 6 months post-treatment, with the self-rated QIDS-SR16 as the primary outcome measure. RESULTS Treatment was generally well tolerated. Relative to baseline, marked reductions in depressive symptoms were observed for the first 5 weeks post-treatment (Cohen's d = 2.2 at week 1 and 2.3 at week 5, both p < 0.001); nine and four patients met the criteria for response and remission at week 5. Results remained positive at 3 and 6 months (Cohen's d = 1.5 and 1.4, respectively, both p < 0.001). No patients sought conventional antidepressant treatment within 5 weeks of psilocybin. Reductions in depressive symptoms at 5 weeks were predicted by the quality of the acute psychedelic experience. CONCLUSIONS Although limited conclusions can be drawn about treatment efficacy from open-label trials, tolerability was good, effect sizes large and symptom improvements appeared rapidly after just two psilocybin treatment sessions and remained significant 6 months post-treatment in a treatment-resistant cohort. Psilocybin represents a promising paradigm for unresponsive depression that warrants further research in double-blind randomised control trials.},\n bibtype = {article},\n author = {Carhart-Harris, Robin Lester and Bolstridge, Mark and Day, Camilla M.J. and Rucker, James J.H. and Watts, Rosalind and Erritzoe, David and Kaelen, Mendel and Giribaldi, B and Bloomfield, Michael and Pilling, Steve and Rickard, James A. and Forbes, Ben and Feilding, Amanda and Taylor, David and Curran, H. Valerie and Nutt, David J.},\n journal = {Psychopharmacology},\n number = {2}\n}","author_short":["Carhart-Harris, R., L.","Bolstridge, M.","Day, C., M.","Rucker, J., J.","Watts, R.","Erritzoe, D.","Kaelen, M.","Giribaldi, B.","Bloomfield, M.","Pilling, S.","Rickard, J., A.","Forbes, B.","Feilding, A.","Taylor, D.","Curran, H., V.","Nutt, D., J."],"urls":{"Website":"https://doi.org/10.1007/s00213-017-4771-x,http://www.ncbi.nlm.nih.gov/pubmed/29119217%0Ahttp://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC5813086"},"bibbaseid":"carhartharris-bolstridge-day-rucker-watts-erritzoe-kaelen-giribaldi-etal-psilocybinwithpsychologicalsupportfortreatmentresistantdepressionsixmonthfollowup-2018","role":"author","keyword":["5-HT2AR","Depression","Hallucinogen","Mood","Psilocybin","Psychedelic","Psychotherapy","Serotonin","Treatment-resistant depression"],"downloads":0},"bibtype":"article","creationDate":"2019-07-17T21:06:58.259Z","downloads":0,"keywords":["5-ht2ar","depression","hallucinogen","mood","psilocybin","psychedelic","psychotherapy","serotonin","treatment-resistant depression"],"search_terms":["psilocybin","psychological","support","treatment","resistant","depression","six","month","follow","carhart-harris","bolstridge","day","rucker","watts","erritzoe","kaelen","giribaldi","bloomfield","pilling","rickard","forbes","feilding","taylor","curran","nutt"],"title":"Psilocybin with psychological support for treatment-resistant depression: six-month follow-up.","year":2018}